About this trial
Warfarin is a commonly used blood thinner to treat and prevent blood clots. It is important to take the right dose of warfarin because too much can increase the risk of bleeding and too little can increase the risk of blood clots. This is why patients are closely monitored especially when they begin warfarin therapy. When clinicians prescribe warfarin, they have to consider different factors such as patient's age, body size, diet, and other medications that can interact with warfarin.
Certain genes have also been found to affect warfarin dose. Individuals have variations in these genes, which can help explain why some patients need higher dose and others require less. These factors have been used to better predict a patient's warfarin dose requirement. However, these predictions were created based on Caucasian populations and they may not be accurate in predicting a safe warfarin dose if a patient is not Caucasian. This study aims to identify new genetic variation that affects warfarin dosing in Hispanic and Latino populations and try to better predict a Hispanic or Latino patient's warfarin dose requirement.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
At least 18 years of age
Ability to give informed consent
Therapeutic INR for at least 2 consecutive clinic visits
Self-identifies as Hispanic or Latino
Disqualifiers
Less than 18 years old
Unable to give informed consent
Severe hepatic impairment
Trial population
The study population will be Hispanic and Latino patients on stable doses of warfarin therapy.
Trial design
Cohort
Prospective
Treatments tested in this trial
Mouthwash sample
Procedure/SurgeryA one time mouthwash sample will be performed.
Blood Draw
Procedure/SurgeryPatients who are receiving a blood draw during their regular clinical appointment will be asked for a blood sample of 15 milliliters. Genomic DNA will be isolated for genotyping and patient plasma samples will also be stored.
Treatment groups
Trial outcomes
Primary outcomes
Stable warfarin dose
Dose of warfarin required to maintain stable INR for at least 2 consecutive clinic visits.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.